These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17875661)

  • 1. Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL.
    Dorshkind K; Witte ON
    Genes Dev; 2007 Sep; 21(18):2249-52. PubMed ID: 17875661
    [No Abstract]   [Full Text] [Related]  

  • 2. [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib].
    Han W; Liu KY; Xu LP; Chen H; Liu DH; Chen YH; Zhang XH; Zhang YC; Chen Y; Wang Y; Wang J; Lu DP; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1974-7. PubMed ID: 19062738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.
    Costa LJ
    Br J Haematol; 2009 Sep; 146(5):576-7. PubMed ID: 19555375
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal antibodies and complement purged autograft in Burkitt lymphoma and lymphoblastic leukemia.
    Favrot M; Philip I; Combaret V; Pavone E; Bouffet E; Biron P; Philip T
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():202-4. PubMed ID: 2713555
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
    Strout MP; Schatz DG
    Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PDE model for imatinib-treated chronic myelogenous leukemia.
    Kim PS; Lee PP; Levy D
    Bull Math Biol; 2008 Oct; 70(7):1994-2016. PubMed ID: 18663536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical models of cancer stem cells.
    Michor F
    J Clin Oncol; 2008 Jun; 26(17):2854-61. PubMed ID: 18539964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive thoughts about progressive disease.
    Shah NP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748
    [No Abstract]   [Full Text] [Related]  

  • 9. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.
    Burke MJ; Trotz B; Luo X; Baker KS; Weisdorf DJ; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Jan; 43(2):107-13. PubMed ID: 18776928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
    Williams RT; Sherr CJ
    Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukaemia.
    Mandavilli A
    Nature; 2013 Jun; 498(7455):S1. PubMed ID: 23803941
    [No Abstract]   [Full Text] [Related]  

  • 14. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
    Pocaly M; Lagarde V; Etienne G; Dupouy M; Lapaillerie D; Claverol S; Vilain S; Bonneu M; Turcq B; Mahon FX; Pasquet JM
    Proteomics; 2008 Jun; 8(12):2394-406. PubMed ID: 18563733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Matsue K; Aoki T; Odawara J; Kimura S; Yamakura M; Takeuchi M
    Leuk Res; 2009 Jun; 33(6):867-9. PubMed ID: 18951628
    [No Abstract]   [Full Text] [Related]  

  • 17. Getting to the stem of chronic myeloid leukaemia.
    Savona M; Talpaz M
    Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Yanada M
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():479-82. PubMed ID: 17474451
    [No Abstract]   [Full Text] [Related]  

  • 19. Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation.
    Merante S; Colombo AA; Calatroni S; Rocca B; Boni M; Bernasconi P; Bonvini L; Soverini S; Alessandrino EP
    Bone Marrow Transplant; 2009 Aug; 44(4):263-4. PubMed ID: 19204710
    [No Abstract]   [Full Text] [Related]  

  • 20. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.